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Abstract
Streptococcus pneumoniae is the most common pathogen causing non-epidemic bacterial meningitis worldwide. The
immune response and inflammatory processes contribute to the pathophysiology. Hence, the anti-inflammatory
dexamethasone is advocated as adjuvant treatment although its clinical efficacy remains a question at issue. In
experimental models of pneumococcal meningitis, dexamethasone increased neuronal damage in the dentate gyrus. Here,
we investigated expressional changes in the hippocampus and cortex at 72 h after infection when dexamethasone was
given to infant rats with pneumococcal meningitis. Nursing Wistar rats were intracisternally infected with Streptococcus
pneumoniae to induce experimental meningitis or were sham-infected with pyrogen-free saline. Besides antibiotics, animals
were either treated with dexamethasone or saline. Expressional changes were assessed by the use of GeneChipH Rat Exon
1.0 ST Arrays and quantitative real-time PCR. Protein levels of brain-derived neurotrophic factor, cytokines and chemokines
were evaluated in immunoassays using Luminex xMAPH technology. In infected animals, 213 and 264 genes were
significantly regulated by dexamethasone in the hippocampus and cortex respectively. Separately for the cortex and the
hippocampus, Gene Ontology analysis identified clusters of biological processes which were assigned to the predefined
categories ‘‘inflammation’’, ‘‘growth’’, ‘‘apoptosis’’ and others. Dexamethasone affected the expression of genes and protein
levels of chemokines reflecting diminished activation of microglia. Dexamethasone-induced changes of genes related to
apoptosis suggest the downregulation of the Akt-survival pathway and the induction of caspase-independent apoptosis.
Signalling of pro-neurogenic pathways such as transforming growth factor pathway was reduced by dexamethasone
resulting in a lack of pro-survival triggers. The anti-inflammatory properties of dexamethasone were observed on gene and
protein level in experimental pneumococcal meningitis. Further dexamethasone-induced expressional changes reflect an
increase of pro-apoptotic signals and a decrease of pro-neurogenic processes. The findings may help to identify potential
mechanisms leading to apoptosis by dexamethasone in experimental pneumococcal meningitis.
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Introduction
Treatment of bacterial meningitis (BM) with sulfonamids was
successfully introduced in the 1930’s and the advent of third
generation cephalosporins further reduced the mortality rates [1].
Since then, improvements in treatment success are scarce and the
mortality rate of BM still reaches 34% and up to 50% of the
survivors suffer from neurologic sequelae [2,3]. Among the
different pathogens causing community-acquired meningitis in
industrialized countries, Streptococcus pneumoniae accounts for the
majority of cases and shows the highest mortality rate [1,4,5,6].
Studies investigating the pathophysiology of BM revealed that
not only the pathogen itself exerts harmful effects but also the
pronounced immune response of the host [4,7]. Neurological
complications such as increased intracranial pressure, cerebral
ischemia, brain edema formation or hydrocephalus can lead to a
fatal outcome [7]. Histopathological assessments in experimental
models as well as autopsy cases showed three forms of injury in the
central nervous system: apoptosis occurs in the hippocampal
dentate gyrus, necrosis is found in the cerebral cortex, and loss of
type 1 neurons in the spiral ganglion. These forms of neuronal
damage cause neurological sequelae such as learning deficits,
seizure disorders and hearing impairments respectively [8,9,10].
In order to reduce the inflammatory reaction, the glucocorticoid
(GC) dexamethasone (dex) is advocated in patients with BM in
addition to antibiotic treatment. Implementation of adjuvant
therapy with dex (10 mg IV, given every 6 hours for 4 days started
before or with the first dose of parenteral antibiotics) reduced
mortality rate and the proportion of patients with unfavorable
outcomes in the Netherlands [11]. Worldwide however, a meta-
analysis including 2029 individual patient data concluded that the
benefit of dex in BM remains unproven [12].
In experimental models both, detrimental and beneficial effects
of adjunctive dex have been observed. Dex increased the number
of apoptotic cells in the hippocampal dentate gyrus of infant rats
with pneumococcal meningitis (PM) and of rabbits with Escherichia
coli or PM [13,14,15] and led to decreased learning performance
[13]. In different animals models however, Dex was shown to have






































otoprotective effects in experimental pneumococcal meningitis in
gerbils [16,17] or rabbits [18], and to improve neurobehavioral
performance in adult rats with group B streptococcal meningitis
[19].
A study assessing the transcriptome in experimental PM
identified Gene Ontology (GO) terms related to ‘‘neuron
generation’’ and ‘‘nervous tissue development’’ to be overrepre-
sented when comparing the hippocampus of infected vs. sham-
infected rats at one and three days after infection [20]. While these
processes were mostly downregulated at day one, they were largely
upregulated at day three. Thus, in this experimental disease
model, the late acute phase until about three days after infection
may offer a window of opportunity for therapeutic interventions to
support neuronal regeneration. Besides its anti-inflammatory
effects, dex is also reported to decrease neural proliferation and
to act pro-apoptotic on neural precursors and immature neurons
[21,22,23]. Therapies that act anti-proliferative, including dex,
may impede regeneration by neurogenesis when administered at
this disease stage [21,24].
In the present study we investigated the effect of dex on the gene
expression profile of the hippocampus and cortex in an infant rat
model of PM 3 days after infection. The rationale for performing
the analysis at the specific time point lies in the fact that in patients
with meningitis, antibiotic therapy and adjuvant therapy with dex
is initiated at this disease stage, and we therefore focused our
investigation on the impact of dex on the early regenerative
processes in the hippocampus. In experimental models of BM,
gene expression analysis revealed regenerative processes to
predominate over inflammatory processes in the hippocampus at
this phase of disease [20]. Using the GO terms of biological
processes we identified genes regulated by dex which are
associated with the most important processes. These findings help
to understand the impact of dex on BM.
Methods
Ethics Statement
All animal studies were approved by the Animal Care and
Experimentation Committee of the Canton of Bern, Switzerland
(Nr. 26/07), and followed the Swiss national guidelines for the
performance of animal experiments.
Animal model
A well established infant rat model of PM was used
[13,25,26,27]. Eleven days old nursing Wistar rats (n = 32) were
infected intracisternally with 10.0 ml sterile saline containing
1.4610665.56105 colony forming units (cfu)/ml of Streptococcus
pneumoniae serotype 3 which has been isolated from a patient with
invasive disease. Sham-infection for control animals (n = 24) was
done with an equal volume of sterile saline 0.85%. Cerebrospinal
fluid (CSF) was obtained by intracisternal puncture at 18 h after
infection and 5 ml were cultured in serial dilutions on blood-agar
plates to assess bacterial load [13,26]. Clinical assessment was
done by weighing the animals and applying a scoring system at
predetermined time points (24 h, 48 h and 72 h after infection)
[27]. Animals with a clinical score lower than 2 were euthanized
for ethical reasons.
Antibiotic and adjuvant treatment of previous experimental PM
studies in infant rats was adopted [13,26]. Antibiotic therapy was
started 18 h after infection in all animals by administration of
ceftriaxone twice a day (100 mg/kg body weight intraperitoneal-
ly). Infected and control animals were then randomized to receive
either saline (0.85% sterile saline sc, tid, n = 16 for infected and
n=12 for control animals) or an equal volume of saline containing
dex (0.7 mg/kg body weight sc, tid, n = 16 for infected and n= 12
for control animals).
The animals were sacrificed 72 h after infection with an
overdose of pentobarbital. Animals were perfused via the left
cardiac ventricle using ice-cold phosphate-buffered saline (PBS).
Then the brain was removed. Hippocampus and cortex were
dissected from one hemisphere in ice-cold PBS and placed in tubes
containing 500 ml and 1000 ml RNAstable reagent, respectively
(kindly provided by Prof. Dr. phil. nat. Rolf Jaggi, Department of
Clinical Research, University of Bern, Switzerland). The samples
were kept at 4uC overnight and subsequently stored at 220uC
until RNA isolation. The contralateral hemisphere was fixed and
cryosections were prepared. The sections were stained with cresyl
violet and evaluated for apoptosis in the dentate gyrus and
ischemic tissue damage to the cerebral cortex as described
elsewhere [13].
Experimental setup
The experiments were designed to yield samples of the
hippocampus and cortex from 4 experimental groups. Samples
of the hippocampus derived from control animals treated with
saline (HCCS), from control animals treated with dex (HCCD),
from infected animals treated with saline (HCIS) and from infected
animals treated with dex (HCID). The samples of the cortex
derived from the equal experimental groups: from control animals
treated with saline (CXCS), from control animals treated with dex
(CXCD), from infected animals treated with saline (CXIS) and
from infected animals treated with dex (CXID).
RNA isolation
Total RNA of hippocampus and cortex was isolated using the
EZ1 RNA Universal Tissue Kit and the EZ1 BioRobot (Qiagen,
Hombrechtikon, Switzerland) according to the manufacturer’s
protocol. The tissue samples were placed in a tube containing
750 ml and 3.0 ml QIAzol Lysis reagent for the hippocampus and
cortex, respectively. Homogenization was done for 30 s with a
rotor-stator homogenizer (TissueRuptor, Qiagen). After five
minutes of incubation at room temperature, 750 ml of the
hippocampus and cortex homogenates were transferred to a new
tube and 150 ml of chloroform were added. The samples were
shaken vigorously and incubated at room temperature for two
minutes. For optimal phase separation, the samples were
centrifuged at 1290006 g for 15 minutes at 4uC. For the
magnetic-particles based purification with the EZ1 RNA Universal
Tissue Kit, 300 ml of the topmost aqueous phase was used as
starting material. The DNase digestion step suggested in the
protocol was included. The RNA was eluted in 50 ml elution
buffer. Total RNA was stored at 280uC until use for microarray
hybridisation and quantitative real-time PCR (qPCR).
In order to assess the quality of the isolated RNA, the Agilent
Bioanalyzer 2100 was used with the RNA 6000 Nano Assay Kit.
The manufacturer’s protocol was followed. The implemented
RNA integrity number (RIN) was used to estimate the quality of
total RNA and to detect potential degradation. The concentration
of total RNA was determined by measuring the absorbance at
260 nm with a spectrophotometer.
RNA processing for hybridisation on GeneChipH Rat Exon
1.0 ST Microarrays
Total RNA was processed following the GeneChipH Whole
Transcript Sense Target Labelling Assay Manual, Version 4
(Affymetrix, Santa Clara, CA, USA). RNA and DNA concentra-
tions were determined with a spectrophotometer. The quality
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control of rRNA-reduced RNA and fragmented DNA was
performed with the Agilent Bioanalyser 2100.
The starting amount was 1.5 mg total RNA. rRNA reduction
was performed and the quality of the resulting RNA was assessed
after column-based purification. Then, the RNA was used to
synthesize double-stranded cDNA which was in vitro transcribed
to antisense cRNA. After cleanup, 10 mg cRNA was used to
generate sense cDNA. The cRNA was hydrolysed with RNaseH
and the cDNA was purified using columns. Of each sample, 5.5 mg
cDNA was fragmented and subsequently verified for its quality.
Fragmented cDNA was labelled with biotin and added to the
hybridisation cocktail at a concentration of 25 ng/ml. The
hybridisation cocktail was then injected into GeneChipH Rat
Exon 1.0 ST Arrays and the arrays were incubated at 45uC on a
rotator in the hybridization oven 640 for 17 h at 60 rpm. The
arrays were washed and stained on a Fluidics Station 450
according to the Fluidics Procedure FS450_0001. The Arrays
were processed with the GeneChipH Scanner 3000 7G. DAT
image and CEL intensity files of the microarrays were generated
using the Affymetrix GeneChipH Command Console (version
0.0.0.676, Affymetrix).
Datamining of microarray data
All data is MIAME compliant and has been deposited in the
ArrayExpress database of the European Bioinformatics Institute
(http://www.ebi.ac.uk/arrayexpress, accession number E-MEXP-
2953).
Data analysis was performed using the oneChannel Graphical
User Interface (version 1.12.1, www.bioinformatica.unito.it/
oneChannelGUI) [28] which is a package available in
Bioconductor open source software for bioinformatics (www.
bioconductor.org) [29] and implemented in the R Project for
Statistical Computing (version 2.10.0, www.r-project.org) [30].
Quality control of the CEL files was done using Expression
Console software (version 1.1, Affymetrix). All CEL files were
deemed suitable for analysis and they were uploaded to
oneChannelGUI using Affymetrix Power Tools (Version
1.12.0, www.affymetrix.com/partners_programs/programs/de-
veloper/tools/powertools.affx). The model-based Robust Multi-
array Average (RMA) algorithm was used to generate the probe
set summary based on the full annotation on gene- and exon-
level [31].A filtering step was introduced and only genes that are
expressed above a defined intensity threshold of 132.5 on 10%
of the arrays were retained, i.e. at least on 3 of 28 arrays. The
limma algorithm was used to compute a linear model fit [32].
For significance testing, the different groups within one tissue
were compared one by one, e.g. HCID vs. HCIS or CXCD vs.
CXCS. The Benjamini and Hochberg procedure was used to
correct for multiple testing [33]. Genes with a false discovery
rate less than 0.05 were considered as differentially expressed.
Only genes with a unique Entrez Gene identifier (ID) were used
for further analysis.
Correspondence Analysis (COA). As previously described,
a COA was done to reduce the data to variables which can be
displayed in a three-dimensional graphic [20]. The analysis was
based on log2-intensities.
GO analysis of biological processes. The functional annot-
ation clustering tool of the Database for Annotation, Visualization,
and Integrated Discovery (DAVID, david.abcc.ncifcrf.gov) was used
to search for clusters of biological processes of the GO database
within two sets of differentially expressed genes, namely HCID vs.
HCIS and CXID vs. CXIS (http://david.abcc.ncifcrf.gov) [34,35].
The list of all genes expressed above the intensity threshold with an
ID was used as background. The default annotation category for
biological processes of GO (GOTERM_BP_FAT) and the medium
classification stringency settings were selected. GO clusters with an
enrichment score greater than 1.3 were considered significant
[35,36]. These clusters were grouped to predefined generic
categories which were ‘‘inflammation’’, ‘‘growth’’, ‘‘apoptosis’’,
‘‘immune system development’’, ‘‘signalling’’, ‘‘hypoxia’’. Multiple
GO clusters were not assigned to one of these categories due to lack
of coherence.
RNA processing for qPCR using TaqMan Low Density
Arrays
Reverse transcription was performed with 1.5 ng total RNA
using the High-Capacity cDNA Reverse Transcription Kit
including the RNase inhibitor (Applied Biosystems, Foster City,
CA). The manufacturer’s protocol was followed. An additional
RT-negative reaction without adding the transcriptase was run for
each sample using one third of RNA input and volumes. The
reaction volume was 20 ml and the standard cycling protocol was
used.
RT-positive and -negative cDNA (75 ng) was controlled for
successful reverse transcription and the absence of genomic DNA
with TaqMan Gene Expression Assays (Applied Biosystems). The
three genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH), trans-
membrane protein (Tmem) 111 and vesicle docking protein USO1 homolog
(USO1) were used in PCR. The manufacturer’s protocol was
followed. TaqMan Gene Expression Master Mix was used and the
standard cycling protocol was run.
The expression of 48 selected genes was assessed in qPCR using
TaqMan Low Density Arrays (Applied Biosystems). Pre-designed
TaqMan Gene Expression Assays were chosen to generate a
customized array. The manufacturer’s protocol was followed and
the arrays were run on a 7900HT Real-Time PCR System
operated by the Sequence Detection Systems software (Version
2.3, Applied Biosystems). The input was 200 ng of cDNA for each
sample. The TaqMan Universal PCR Master Mix was used and
the standard cycling protocol was followed. Four arrays were run
and the data were combined using the RQ Manager software
(Version 1.2, Applied Biosystems). Raw Cq values were exported
for further analysis.
Data analysis of qPCR
The qPCR results were analysed using the DDCq method
implemented in the online tool RT2 Profiler PCR Array Data
Analysis (http://www.sabiosciences.com/pcr/arrayanalysis.php;
SABiosciences, Frederick, MD, USA). No adjustment for primer
efficiency was done because all pre-designed TaqMan Gene
Expression Assays have been thoroughly tested by Applied
Biosystems and are declared to have equivalent amplification
efficiencies close to hundred percent [37]. The cut-off Cq was 35
cycles and to normalize gene expression, the geometric mean of
the reference genes was used. GAPDH as a widely used reference
gene was adopted and supplemented by USO1, Tmem111 and
ribosomal protein L24 (Rpl24). The supplemental reference genes
were selected based on the data of a previous microarray study in
infant rats suffering from PM [20,38]. As suggested in previous
work, genes that showed a coefficient of variance of the raw Cq
values greater than 4% were excluded from further evaluation
[39].
Assessments on the protein level
Protein isolation. In order to obtain tissue samples for
protein extraction, the same procedures as for RNA extraction
were followed on the experimental model of meningitis.
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Additionally, CSF was sampled by intracisternal puncture at 26 h
and 72 h after infection. After the dissection of hippocampus and
cortex, the tissue sample was weighed and supplemented with
seven times as much PBS (1:7 m:v) containing 0.1% Triton-X 100,
Complete Protease Inhibitor Cocktail Tablets H and phosphatase
inhibitors, i.e. 16 Phosphatase Inhibitor Cocktail 1 H (both from
Roche Diagnotics AG, Rotkreuz, Switzerland), 1 mM sodium
orthovanadate, 1 mM sodium fluoride, 20 mM sodium
pyrophosphate and 2 mM beta-glycerophosphate. The tissue
was homogenized and the suspension incubated on ice for
20 min. After centrifugation at 4uC and 1690006 g for 5 min,
the supernatant was collected and stored at 280uC until further
processing.
Measurement of protein concentration. The protein
concentration was measured with the bicinchoninic acid (BCA)
protein assay (Thermo Fisher Scientific Inc., Rockford, IL, USA).
Bovine serum albumin in concentrations between 0 and 2000 mg/
ml was used as standard curve. The hippocampus and cortex
samples were diluted 1:50 and 1:100 respectively with PBS
containing 0.1% Triton-X 100. Then, 25 ml sample or standard
were added with 200 ml working reagent in duplicates to a
microplate. Incubation was done at 37uC for 30 min. The
colorimetric measurement at 550 nm was done with a
microplate reader at room temperature. Protein concentrations
were calculated with the implemented ‘‘Protein Quantification
with BCA’’ protocol in SoftMax Pro software (Version 5.3,
Molecular Devices).
Western blotting. Proteins were separated with a 10%
sodium dodecylsulfate polyacrylamide gel electrophoresis.
Sample, 4x sample buffer containing 5% beta-mercaptoethanol
and water were mixed to a final protein concentration of 50 mg
and a volume of 20 ml. Denaturing was done at 95uC for 5 min
and was followed by electrophoresis at 100 V for 1 h and 50 min.
The separated proteins were transferred to a Polyvinylidene
fluoride membrane (0.45 mm) in a tank transfer system with
transfer buffer (25 mM Tris(hydroxymethyl)-aminomethan (Tris),
192 mM glycine, 20% methanol and 0.05% SDS) at 90 V for 2 h.
The membrane was washed with Tris-buffered saline containing
0.05% Tween 20 (TBST) and blocked for 1 h with 5% milk in
TBST. Incubation with the primary antibody against protein
tyrosine phosphatase, non-receptor type 6 (PTPN6) (1:500 in TBST;
68 kDa; 3759S, Cell Signaling Technology, Danvers, MA, USA)
was done at 4uC overnight. The membrane was washed and
incubated for 1 h at room temperature with the secondary
antibody coupled to peroxidase (1:209000 in TBST; A1949,
Sigma-Aldrich). Chemiluminescent detection was performed for
5 min with luminal as horseradish peroxidase substrate. Protein
signals were detected by exposure of the membrane to medical X-
ray films and developed with an image processor. The membrane
was stripped at 37uC for 20 min. A wash step followed and the
reprobing procedure started at the blocking step. The primary
antibody against beta-actin (1:109000 in TBST; 42 kDa; A5316,
Sigma-Aldrich) and its corresponding secondary antibody
(1:209000 in TBST; A9309, Sigma-Aldrich) were used.
LuminexH xMAPH technology. MILLIPLEX MAP kits
(Millipore Corporation) were used for microsphere-based
multiplex immunoassays to measure the concentration of
different proteins [25]. Brain-derived neurotrophic factor
(BDNF) was measured in homogenates of the hippocampus and
cortex using a single-plex Rat Pituitary Kit. The following
cytokines and chemokines were measured in CSF at 26 h and
72 h after infection, and tissue homogenates using a ten-plex Rat
Cytokine Kit: Interleukin 1 beta (IL-1b), IL-2, IL-6, IL-10,
chemokine C-C motif ligand 2 (CCL2), CCL3, CCL5, chemokine
C-X-C motif ligand 10 (CXCL10) interferon gamma (IFN-g) and
tumor necrosis factor alpha (TNF-a). The cytokines/chemokines
assessed were selected for analysis based on results from previous
studies in the experimental model [25,40]. The manufacturer’s
protocol of each kit was followed. PBS containing 0.1% Triton-X
100 and 5 mg/ml bovine serum albumin was used as matrix. CSF
samples were prepared in a fivefold dilution and the tissue
homogenates were standardized to the smallest protein
concentration detected in the homogenates. At least 100 beads
were counted per analyte. Analysis of raw data was done with the
BIO-PLEX manager software (Version 4.1, BioRad Laboratories,
Hercules, CA, USA). Statistical analyses were done with the
GraphPad Prism software (Version 5.01, GraphPad Software, La
Jolla, CA). The non-parametric Kruskal-Wallis test was used to
compare all groups within the time point or tissue. When this test
was significant, infected and dex-treated animals were compared




The CSF samples of the infected animals showed positive
cultures for Streptococcus pneumoniae at 18 h after infection
documenting successful infection (1.26106 cfu/ml–1.36108 cfu/
ml). No difference between ID vs. IS was observed. The infected
animals showed clinical signs of disease reflected by weight loss
(24 h, 48 h and 72 h after infection) and reduced clinical scores
(24 h and 72 h after infection) (Table 1). Five infected animals of
both treatment groups were euthanized because they showed a
clinical score lower than 2. Animals with PM showed a
significantly reduced weight in comparison to sham-infected
animals (p,0.001 using the unpaired t test for all time points).
Dex significantly decreased the weight of control animals at all
time points and in infected animals only at 72 h after infection
(p,0.01 using the unpaired t test). In order to induce a uniform
disease with low mortality, a moderate disease severity was
induced which did not result in ischemic tissue damage to the
cerebral cortex at 72 h after infection. The number of apoptotic
cells was not significantly different when comparing ID vs. IS
(p = ns using the Mann Whitney U test).
RNA isolation
All RNA samples fulfilled the minimal quality requirements of a
RIN.7.0 [41,42,43]. Based on the high quality of the isolated
RNA we excluded samples with a RIN,8.0. The RIN of the
samples used for microarray hybridization was 8.760.3 (mean 6
SD) and it was 8.860.2 for the samples used in qPCR analysis.
RNA processing for hybridisation on GeneChipH Rat Exon
1.0 ST Microarrays
The RIN and the weight difference of the animals at 48 h after
infection were used as parameters to reduce variability from the
starting material. Outliers regarding the weight showed weight
gain in infected animals or no weight gain in control animals.
Based on this criterion, one animal per group was excluded from
further selection. Six samples (26 CXIS; 16 CXID; 26 CXCS
and 16HCCS) showed a RIN lower than 8 and were therefore
excluded. From the remaining samples, 4 hippocampal and
cortical samples of ID and IS animals were randomly chosen while
3 samples were randomly chosen of ID and IS animals.
In order to increase array detection sensitivity and specificity,
rRNA reduction was performed. Evaluation of the Bioanalyzer
2100 plots showed appropriate quality for all samples at both in-
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process checkpoints during RNA preparation, i.e. after rRNA
reduction and fragmentation of DNA.
Datamining of microarray data
Overview. Raw and normalized data are available in the
ArrayExpress database of the European Bioinformatics Institute
(http://www.ebi.ac.uk/arrayexpress, accession number E-MEXP-
2953). 1879014 probesets were available for analysis when the full
annotation option was selected for upload of the data to
oneChannelGUI (Figure 1). The number of probesets was
reduced to 149509 by removing probesets expressed below the
defined background threshold. After applying the linear model fit,
paired comparisons of experimental groups resulted in the
following numbers of significantly up- and downregulated genes
with an identifier (Figure 2). The highest number of genes was
regulated when comparing IS vs. CS, i.e. 390 genes in the
hippocampus and 380 genes in the cortex. Of these genes, 78%
were upregulated in both tissues. Approximately half as many
genes changed their expression when comparing ID vs. CD. In
this comparison, 98% of 177 genes were upregulated in the
hippocampus and 97% of 166 genes were upregulated in the
cortex. The comparison of ID vs. IS revealed expressional changes
in 213 genes in the hippocampus and 264 genes in the cortex
showing 34% and 52% upregulation respectively. The least genes
were regulated when comparing CD vs. CS.
Venn diagrams. Venn diagrams help to understand the
relation of regulated genes between different given comparisons.
They allow identifying the number of genes regulated by multiple
comparisons. When looking for the effect of the treatment, 25 genes
in the hippocampus and 43 genes in the cortex were regulated by
dex regardless of the infection status (Figure 3). 188 genes in the
hippocampus and 221 genes in the cortex changed their expression
only when infected animals were treated with dex. It was also shown
that 164 genes in the hippocampus and 149 genes in the cortex were
regulated by the infection irrespective of the treatment.
COA. The COA reduced the multidimensional microarray
data to the three most informative components describing the
dataset. Samples that are close to one another on the plot show
similar expression profiles. All experimental groups were separated
from each other and the respective samples clustered together
(Figure 4). The first component that explains most of the variance
in the data set separated infected animals and control animals.
The second component discriminated between hippocampus and
cortex samples. The third component separated dex-treated and
saline-treated animals. These three components found in
unsupervised dimension reduction reflect the experimental setup
and validate the dataset.
GO analysis. In the hippocampus, the functional annotation
clustering tool of DAVID generated 68 GO clusters of biological
processes out of the differentially regulated genes when comparing
ID vs. IS. Twenty-five of these GO clusters showed an enrichment
score greater than 1.3. In the cortex, 81 GO clusters were formed
but only 15 of them showed an enrichment score greater than 1.3.
The genes associated to specific GO clusters were then
summarized in six defined categories (Tables S1 and Table S2).
The three categories with the highest numbers of regulated genes
Table 1. Overview of the clinical parameters of all experimental groups.
Animal status
Weight difference
at 24 h pi [g]
Weight difference
at 48 h pi [g]
Weight difference
at 72 h pi [g]
Clinical score
at 24 h pi
Clinical score
at 72 h pi
Number of
apoptotic cells
Control + saline (n = 7) 3.460.5 5.161.2 6.462.5 5.060.0 5.060.0 0.1 [0.0–0.5]
Control + dexamethasone (n = 7) 2.360.5 2.160.4 2.661.3 5.060.0 5.060.0 2.2 [0.2–3.9]
Infected + saline (n = 8) 20.561.1 22.161.7 20.462.0 4.060.8 3.960.4 0.1 [0.0–0.2]
Infected + dexamethasone (n = 8) 21.360.9 23.661.0 23.161.5 3.960.4 3.960.4 0.0 [0.0–0.4]
The number of animals include all animals used for the microarray experiment only or used for the microarray experiment and the qPCR analysis. Mean 6 standard
deviation are given for weight difference and clinical score, median and [range] are given for the number of apoptotic cells. pi = post infection.
doi:10.1371/journal.pone.0017840.t001
Figure 1. Workflow of the gene expression analysis of the
microarray data. Square textboxes represent the gene lists at the
different steps of the workflow and round-edged textboxes represent
the different steps performed for data analysis. RMA=Robust Multi-
array Average, FU= fluorescence units, id = identifier.
doi:10.1371/journal.pone.0017840.g001
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were ‘‘inflammation’’, ‘‘growth’’ and ‘‘signalling’’ in both tissues
(Figure 5). ‘‘Inflammation’’ included the highest number of genes
in the hippocampus while it included less genes than ‘‘growth’’ and
‘‘signalling’’ in the cortex. More regulated genes were found in
‘‘growth’’ than in ‘‘signalling’’ in both tissues. With the exception
of the category ‘‘signalling’’ in the cortex, all these categories
included more down- than upregulated genes. Likewise, more
down- than upregulation was observed in the categories ‘‘immune
system development’’ and ‘‘apoptosis’’. While ‘‘immune system
development’’ included more regulated genes than ‘‘apoptosis’’ in
the hippocampus, the latter one included more genes than
‘‘immune system development’’ in the cortex. The category
‘‘hypoxia’’ included the least regulated genes in the hippocampus
and was not represented in the cortex.
RNA processing for qPCR using TaqMan Low Density
Arrays
The 14 samples from the hippocampus used for microarray
hybridisation were also analyzed by qPCR analysis. Per group,
four additional hippocampal samples from littermates were run in
qPCR (n= 8 for infected animals, n = 7 for sham-infected
animals).
Successful reverse transcription was confirmed by the quality
check of the cDNA using the assays for the reference genes
GAPDH, USO1 and Tmem111. All reverse transcribed samples
were detected by all three PCR reactions. Of the three reference
genes, solely GAPDH is able to detect genomic DNA since its
primers are positioned within a single exon. Genomic DNA was
detected in multiple RT-negative samples, but the Cq value was
greater than 35 which was defined as sensitivity threshold for
qPCR evaluation. Furthermore, the Cq value of the RT-negative
sample was more than 15 times greater than the one in the RT-
positive sample indicating a difference in DNA amount of a factor
of 309000. Hence, the amount of genomic DNA was considered
negligible.
Data analysis of qPCR
One sample of the infected and dex-treated animals was
excluded from the analysis based on irregular qPCR plots.
GAPDH was initially used as one of four reference genes.
However, its use as reference gene was questioned in the literature
lately [38,39]. Likewise we observed fluctuations of GAPDH
expression within our experimental setup. Therefore we excluded
it from the list of reference genes. Two genes, namely CXCL10
(ID 245920) and POU class 5 homeobox 1 (POU5f1, ID 294562) were
not analysed due to a coefficient of variance greater than 4%.
In a first step, HCID vs. HCIS were compared (Table S3). The
fold changes of qPCR and microarray analysis showed a highly
significant Spearman correlation of r = 0.804 (p,0.0001). Four-
teen genes were found to be significantly regulated in qPCR
(Table 2). In order to assess the expressional pattern of these genes,
the three experimental groups HCCD, HCIS and HCID were
compared to the control group HCCS (Figure 6). Two
expressional patterns separated these genes. Genes downregulated
by the infection and upregulated by dex were CD47 (ID 29364),
Catenin (cadherin associated protein) beta 1 (Ctnnb1, ID 84353), nerve
growth factor (NGF, ID 310738), neurotrophic tyrosine kinase receptor type
2 (NTRK2, ID 25054) and NTRK3 (ID 29613), TSC 22 domain
family member 3 (TSC22d3, ID 83514) and vascular endothelial growth
factor (VEGFA, ID 83785). The inversed pattern was observed for
the allograft inflammatory factor 1 (AIF-1, ID 29427), the glial fibrillary
acidic protein (GFAP, ID 24387), the NGF receptor (NGFR, ID
24596), the purinergic G-protein coupled receptor P2Y 12 (P2Y12, ID
64803), the pyrimidinergic G-protein coupled receptor P2Y 6 (P2Y6, ID
117264), the transforming growth factor beta 1 (TGF-b1, ID 59086) and
the TGF-b receptor 2 (Tgfbr2, ID 81810).
Figure 2. The numbers of significantly regulated genes by
comparing the different treatment groups. C= control animals,
D = dexamethasone treatment, S = saline treatment, I = infected animals.
doi:10.1371/journal.pone.0017840.g002
Figure 3. Venn diagrams showing the relation of the number of
genes of defined comparisons. The numbers in the left or right part
of the circles represent the number of regulated genes in the given
comparison. The number in the intersection of both circles represents
the number of genes regulated in both comparisons. The influence of
the treatment in infected vs. control animals within the hippocampus
(A) and cortex (B) is shown. The intersection shows the number of
genes which are regulated by the treatment irrespective of the
infection. The influence of the infection in dexamethasone vs. saline
treated animals within the hippocampus (C) and cortex (D) is shown.
The intersection shows the number of genes regulated by the infection
irrespective of the treatment. I = infected animals, D = dexamethasone
treatment, S = saline treatment, C = control animals.
doi:10.1371/journal.pone.0017840.g003
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Assessments on the protein level
Western blotting. Analysis of PTPN6 (ID 116689)
expression on the mRNA level showed an increase by the
infection and a reduction by dex in infected animals. These
findings were confirmed on the protein level by western blot
analysis (Figure 7).
LuminexH xMAPH Technology. The protein measurements
in hippocampus and cortex homogenates showed significant
decreases of CCL2, CCL3 and CCL5 when comparing ID vs.
IS (Table 3). No changes by dex were observed in the levels of the
other chemokines and cytokines assessed. BDNF was shown to be
constantly higher expressed in the hippocampus than in the
cortex. Within the same tissue, no differences in BDNF protein
levels were observed.
Protein levels in the CSF showed a significant increase in
CXCL10 expression when comparing ID vs. IS at 72 h after
infection (Table 3). In contrast, a decrease in IFN-g levels by dex
was seen in CSF at 72 h after infection.
Discussion
Conducting a microarray experiment yields an enormous
amount of raw data. Appropriate statistical methods are required
to evaluate such data sets and the use of biological databases helps
to circumvent interpretational pitfalls. Due to the limited number
of samples, i.e. four and three samples for infected and sham-
infected animals respectively, the control of the sample variability
is essential. Differences can be introduced by the starting material
and the technical processing.
In the experimental model of meningitis, clinical parameters
such as clinical score and weight difference were assessed at
defined time points. In order to decrease variability within the
starting samples, the weight difference at 48 h after infection was
used. Animals with an outlier value of weight difference were
excluded, e.g. weight gain in infected animals or weight loss in
control animals. In order to process only RNA showing high
Figure 4. The correspondence analysis (COA) of the microarray dataset. The COA separated in component one (x axis in A and B) the
control from the infected animals, in component two (y axis in A) the hippocampus from the cortex samples and in component three (y axis in B) the
dexamethasone treated from the saline treated animals. Each square represents an array. H= hippocampus, C = cortex. Equal numbers in the
hippocampus and cortex group indicates that these samples derived from the same animal.
doi:10.1371/journal.pone.0017840.g004
Figure 5. Gene Ontology (GO) analysis of biological processes.
Infected and dexamethasone-treated animals were compared with
infected and saline-treated animals (ID vs. IS) in the hippocampus (A)
and the cortex (B). GO clusters of biological processes were generated
by the functional annotation clustering tool of the Database for
Annotation, Visualization, and Integrated Discovery (DAVID). These
clusters were then assigned to six defined categories.
doi:10.1371/journal.pone.0017840.g005
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quality, samples with an RIN lower than 8.0 were removed. Three
control animals and 4 infected animals per treatment were chosen
from the remaining samples for the microarray experiment. Four
additional hippocampal samples of littermates per group were
used for qPCR analysis in order to increase the number of
samples.
The technical processing was monitored by in-process quality
controls of the samples during the synthesis of targets for
microarray hybridization. In order to control the hybridization
step, the raw data were evaluated for their accuracy based on
intensity and expression box plots, MA plots and spike-in controls.
All samples passed the different quality check points and were used
for data mining. A COA was performed after the probe
summarization in order to visualize the structure of the
Table 2. Results of the significantly regulated genes on TaqMan Low Density Arrays.









Allograft inflammatory factor 1 (AIF-1) Rn00567906_g1 NM_017196.2 0.526 0.347–0.705 0.648
Glial fibrillary acidic protein (GFAP) Rn00566603_m1 NM_017009.2 0.406 0.269–0.544 0.466
Nerve growth factor, beta (NGF) Rn01533872_m1 XM_227525.3 1.310 1.125–1.495 1.088
Neurotrophic tyrosine kinase, receptor, type 2 (NTRK2) Rn01441749_m1 NM_012731.1 1.380 1.243–1.517 1.171
Neurotrophic tyrosine kinase, receptor, type 3 (NTRK3) Rn00570389_m1 NM_019248.1 1.191 1.057–1.326 1.042
Nerve growth factor receptor (NGFR) Rn00561634_m1 NM_012610.1 0.628 0.447–0.810 1.032
Catenin (cadherin associated protein), beta 1 (Ctnnb1) Rn00584431_g1 NM_053357.2 1.296 1.121–1.471 1.046
Transforming growth factor, beta 1 (TGF-b1) Rn99999016_m1 NM_021578.2 0.565 0.445–0.686 0.635
Transforming growth factor, beta receptor II (Tgfbr2) Rn00579682_m1 NM_031132.3 0.800 0.698–0.902 0.752
CD47 antigen (CD47) Rn00569914_m1 NM_019195.2 1.223 1.115–1.332 1.039
Purinergic receptor P2Y, G-protein coupled 12 (P2Y12) Rn02133262_s1 NM_022800.1 0.351 0.250–0.452 0.497
Pyrimidinergic receptor P2Y, G-protein coupled, 6 (P2Y6) Rn02134326_s1 NM_057124.2 0.464 0.319–0.610 0.544
TSC22 domain family 3 (TSC22d3) Rn00580222_m1 NM_031345.1 2.512 2.095–2.929 1.790
Vascular endothelial growth factor A (VEGFA) Rn01511602_m1 NM_031836.2 1.305 1.050–1.559 1.370
id = identifier, qPCR = quantitative real-time PCR, ID = infected and dexamethasone-treated animals, IS = infected and saline-treated animals, CI = confidence interval,
MA=microarray. A fold change below one shows downregulation, a fold change above one shows upregulation.
doi:10.1371/journal.pone.0017840.t002
Figure 7. Western blot and microarray assessment of tyrosine
phosphatase, non-receptor type 6 (PTPN6). The western blot
analysis showed increased protein levels in hippocampus and cortex
homogenates of infected animals compared to control samples (A). This
finding confirms the results of the microarray experiment (B).
I = infected animals, S = saline treatment, D = dexamethasone treatment,
C = control animals.
doi:10.1371/journal.pone.0017840.g007
Figure 6. Gene expression pattern of the quantitative real-time
PCR analysis in the hippocampus. The three experimental groups
were compared to control and saline-treated animals. These 14 genes
were significantly regulated when comparing infected and dexameth-
asone-treated animals with infected and saline-treated animals (ID vs.
IS). C = control animals, D = dexamethasone treatment, I = infected
animals, S = saline treatment.
doi:10.1371/journal.pone.0017840.g006
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expressional data (Figure 4). The samples were correctly separated
by the three parameters infection, brain region and treatment.
First, this result shows that fundamental differences evoked by
these three parameters do exist and second, that the variability
between the different groups is sufficiently low to allow the
separation of the groups.
Another issue to be addressed when doing a whole genome
expression analysis of brain tissue is the complex functional and
anatomical structure of the brain [20,44]. Different cell types
(e.g. neurons, glial cells and subtypes within) form various brain
areas or are grouped within the same area into structurally
distinct subregions. Moreover, two challenges arise in the
evaluation of expression profiling studies by the heterogeneous
nature of brain tissue. Biologically important differences are
often due to small changes in gene expression [44]. Therefore,
the typically used cut-off level, i.e. greater than a two-fold
change, is not appropriate for expression profiling in brain tissue
which poses the discrimination of real differences from
experimental noise as a significant issue. The other challenge
lies within the relative amount of different cell types [44]. A
significant fold change of one gene can be diluted when
occurring in a cell type representing only a fraction of the
overall cell population being studied. Furthermore, downregu-
lation of a gene in one cell population and upregulation of this
gene in a neighbouring cell population results in an underesti-
mation of the real change.
Microglial cells are the brain resident macrophages of the
central nervous system (CNS). When activated, they play an
important role in both the innate immunity and the pathogenesis
of CNS infections such as BM [45]. Inflammatory mediators and
nitric oxide released by microglial cells can contribute to neuronal
damage. Besides this direct induction of apoptotic death of
neurons, microglial cells indirectly cause neuronal damage by
attracting monocytes and neutrophils. The detrimental effects
manifest on neural stem and progenitor cells, the precursors of
neurons localized in the subgranular zone of the hippocampal
dentate gyrus [46,47]. It is this brain region that shows apoptotic
cell death in experimental BM. In the infant rat model of PM the
extent of apoptosis is further enhanced by dex, an observation that
underlies the present study [13]. Dex as a GC exerts anti-
inflammatory effects and inhibits the expression of pro-inflamma-
tory molecules. Additionally, dex has been shown to suppress
proliferation of neuronal cells [21,22,23].
The impact of dex on inflammation, damage and regeneration
in experimental PM is discussed below with the emphasis on the
hippocampus, a brain structure where these processes overlap.
Therefore, only significant expressional changes when comparing
HCID vs. HCIS will be discussed based on genes assigned to the
categories ‘‘inflammation’’, ‘‘apoptosis’’ and ‘‘growth’’ found in
GO cluster analysis of biological processes (Table 4). A significant
difference of gene expression when comparing CXID vs. CXIS is
mentioned when observed.
Table 3. Results of the multiplex immunoassays in tissue homogenates (A) and/or cerebrospinal fluid (B).
A) Hippocampus [pg/mg total protein] (72 h pi) Cortex [pg/mg total protein] (72 h pi)
Protein CS (n =4) CD (n=4) IS (n =5) ID (n=7) Ratio (ID/IS) CS (n =4) CD (n=4) IS (n=5) ID (n=7) Ratio (ID/IS)
MIP-1a/CCL3 1.70 0.48 6.69 1.76 0.26 * 0.27 0.70 3.78 0.91 0.24 *
MCP-1/CCL2 5.43 8.84 8.84 5.01 0.57 * 3.27 4.77 7.44 3.51 0.47 *
RANTES/CCL5 7.40 8.05 39.59 15.63 0.39 * 6.13 7.10 25.32 10.88 0.43 *
IP-10/CXCL10 - - - - - - - - - -
TNF-a 5.91 7.12 5.93 4.49 0.76 3.38 3.97 2.63 2.24 0.85
IFN-g - - 3.57 5.03 1.41 - - 1.84 2.28 1.24
IL-1b 16.13 13.60 19.28 12.92 0.65 6.92 6.94 17.37 8.59 0.49
IL-2 37.51 39.56 16.80 14.77 0.88 17.57 22.03 15.15 8.69 0.57
IL-6 24.98 18.72 16.35 16.97 1.04 14.77 12.22 8.22 10.54 1.28
IL-10 7.16 6.91 4.60 3.26 0.71 4.18 3.82 2.31 2.52 1.09
BDNF (n = 6 for ‘‘C’’) 52.89 45.53 27.05 59.26 2.19 5.60 4.52 4.88 9.12 1.87
B) 26 h pi in CSF [pg/ml] 72 h pi in CSF [pg/ml]
Protein CS (n =5) CD (n=5) IS (n =5) ID (n=3) Ratio (ID/IS) CS (n =5) CD (n=5) IS (n=4) ID (n=3) Ratio (ID/IS)
MIP-1alpha/CCL3 - - 466.27 536.12 1.15 - - - - -
MCP-1/CCL2 - - 15656.19 22391.21 1.43 - - 654.70 214.34 0.33
RANTES/CCL5 188.74 292.38 1559.93 2601.10 1.67 251.52 314.88 790.91 434.15 0.55
IP-10/CXCL10 121.77 113.08 113.08 183.67 1.62 152.03 137.64 43.97 121.77 2.77 *
TNF-a - - 134.49 231.65 1.72 - - 6.18 14.33 2.32
IFN-g - - 40396.90 36139.64 0.89 - - 186.50 50.83 0.27 *
IL-1b 11.60 11.60 230.18 439.00 1.91 11.60 22.48 11.60 11.60 1.00
IL-2 18.35 18.35 73.78 121.40 1.65 29.83 18.35 37.96 18.36 0.48
IL-6 - - 48328.63 28767.47 0.60 - - - - -
IL-10 - - 2577.83 3846.96 1.49 - - - - -
Results are given as median. ‘‘-’’ indicates values that were below detection limit. * p,0.05 was considered as significantly different. pi = post infection, C = control
animals, S = saline treatment, D = dexamethasone treatment, I = infected animals, CSF = cerebrospinal fluid.
doi:10.1371/journal.pone.0017840.t003
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Inflammation
GCs are the most commonly used anti-inflammatory and
immunosuppressive drugs in a variety of inflammatory and
immune diseases. The anti-inflammatory effect is based on the
activation of anti-inflammatory gene expression and the repression
of pro-inflammatory gene expression [48]. Dex is a synthetic GC
which shows a 20 to 30 times higher potency to evoke anti-
inflammatory effects relative to the endogenously produced
cortisol. Dex was reported to inhibit the activation of microglia
which was confirmed in the qPCR results showing a significant
downregulation of AIF-1, a marker of activated microglia [45,49].
Its expression was found to be increased already in the early acute
phase of experimental BM and peaked at 3 days after infection
[2,20]. Immunohistochemical detection confirmed the expression-
al data and showed the morphological change of microglia from
the resting and ramified shape to the active and amoeboid form
[20,45]. In a rat model of traumatic brain injury, dex was able to
decrease the accumulation of AIF-1-positive cells [49]. CD68
antigen (CD68, ID 287435) is a marker for microglial cells that
have differentiated into a macrophage-like phenotype [20,45].
The downregulation of CD68 by dex in PM confirms the
inhibition of microglial activation. GFAP, which is another glial
marker, assigns the activation of astrocytes and was downregulated
by dex. GFAP expression was upregulated in the cortex and
hippocampus of animals with PM [2,20]. Astrocytes were shown
to rescue neurons from microglial glutamate-induced death by the
uptake of exogenous glutamate via excitatory amino acid
transporters [50]. The excitatory amino acid glutamate was found
to be elevated in the CSF of patients with BM [51]. In addition,
glutamate influx into the peri- and endolymph was suggested to be
a possible link between blood-labyrinth barrier disruption and
hearing loss in BM [52].
Inhibition of microglia activation prevents the production of
chemokines and cytokines [45]. In hippocampus and cortex
homogenates of infected animals we detected significant decreas-
es by dex on the protein level of chemokine C-C motif ligand 2
(CCL2, ID 24770), CCL3 (ID 25542) and CCL5 (ID 81780).
These proteins were reported to be released by microglia when
stimulated with pneumococcal cell wall [53]. CCL2 is a monocyte
chemoattractant protein and recruits macrophages and microglia
to inflammatory sites [54]. CCL2 was observed to be induced in
the acute phase of PM [55]. Dex was shown to inhibit the
production of CCL2 mRNA and protein by activated microglia
resulting in the inhibition of microglial migration [56]. CCL3 was
associated to neutrophil recruitment while CCL5 plays a role in
recruiting leukocytes to inflammatory sites [54]. In the CSF of
infected animals, CXCL10 was upregulated on the protein level
by dex at 72 h after infection. The protein was found to be
induced at 24 h after infection with Streptococcus pneumoniae but was
no longer detected later on [55]. CXCL10 is also known as the
IFN-g-inducible protein. However, we found decreased IFN-g
(ID 25712) protein levels in CSF by dex. Results of the analysis
on the level of gene expression differed from those on the protein
level, indicating that cytokine/chemokines are modulated at both
levels similar to what has been observed in other experimental
paradigms [57].
Table 4. Fold changes of significantly different genes on microarrays which are mentioned in the discussion.





117029 chemokine (C-C motif) receptor 5 (CCR5) 0.329 0.332
171056 chemokine (C-X3-C) receptor 1 (CX3CR1) 0.383 0.414
24387 glial fibrillary acidic protein (GFAP) 0.466 0.451
287526 serine (or cysteine) peptidase inhibitor, clade F, member 1 (Serpinf1) 0.488 -
64803 purinergic receptor P2Y, G-protein coupled 12 (P2Y12) 0.497 -
25124 signal transducer and activator of transcription 1 (STAT1) 0.517 0.553
287435 Cd68 molecule (CD68) 0.532 -
29591 transforming growth factor, beta receptor 1 (Tgfbr1) 0.533 0.556
58962 prostaglandin D2 synthase 2, hematopoietic (HPGDS) 0.572 -
116689 protein tyrosine phosphatase, non-receptor type 6 (PTPN6) 0.585 -
54259 inositol polyphosphate-5-phosphatase D (INPP5D) 0.639 0.694
24404 glutathione peroxidase 1 (Gpx1) 0.667 0.694
308444 Axl receptor tyrosine kinase (Axl) 0.678 0.746
57027 a disintegrin and metallopeptidase domain 17 (ADAM17) 0.700 -
81810 transforming growth factor, beta receptor II (Tgfbr2) 0.752 -
303786 apoptosis-inducing factor, mitochondrion-associated 3 (Aifm3) 2.341 2.205
24484 insulin-like growth factor binding protein 3 (IGFBP-3) 1.932 2.222
83514 TSC22 domain family 3 (TSC22d3) 1.790 2.069
81809 transforming growth factor, beta 2 (TGF-b2) 1.711 1.420
29610 transforming growth factor, beta receptor III (Tgfbr3) 1.525 1.578
81811 thrombopoietin (THPO) 1.336 -
25054 neurotrophic tyrosine kinase, receptor, type 2 (NTRK2) - 1.254
id = identifier, ID = infected and dexamethasone treated animals, IS = infected and saline treated animals. A fold change below one shows downregulation, a fold change
above one shows upregulation.
doi:10.1371/journal.pone.0017840.t004
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Chemokine C-X3-C motif receptor 1 (CX3CR1, ID 171056) was
downregulated by dex in the cortex and the hippocampus. It is a
G-protein-coupled receptor localized on microglial and immune
cells. Its ligand fractalkine is neuronally expressed and may be
involved in the activation and chemoattraction of microglia into
injured tissue following ischemia [58]. CX3CR1 was shown to be
downregulated in the early acute phase (22 h after infection) and
upregulated in the late acute phase (44 h after infection) of BM
[2].
P2Y12 was shown to be downregulated by dex in the
hippocampus by microarray and qPCR assessment. The latter
one additionally detected a downregulation of P2Y6 by dex.
P2Y12 is a receptor at which nucleotides, mainly ATP, induce
microglial chemotaxis towards sites of neuronal damage at early
stages of local CNS injury [59,60,61]. The receptor shows robust
expression in resting microglia which is reduced after microglial
activation. Lack of P2Y12 in knockout mice revealed a significant
delay but no complete abolishment of microglial chemotaxis [60].
When hippocampal neurons were damaged in vivo and in vitro,
an increase in P2Y6 mRNA co-localizing with activated microglia
was observed [62]. The receptor is activated by endogenous UDP
that was leaked by injured neurons triggering microglial
phagocytosis [59,61,62].
Signal transducer and activator of transcription 1 (STAT1, ID 25124)
was downregulated by dex in the hippocampus. It was observed to
be continuously upregulated in the acute phase of BM [2]. STAT1
is directly activated by reactive oxygen species within ischemic
neurons and regulates the cellular response to IFN-g [63]. It was
shown that dex inhibits STAT1 expression when activated by
IFN-g in peripheral blood mononuclear cells [64]. The observed
reduction of IFN-g protein level by dex in experimental PM may
add to the decrease of STAT1 expression.
ADAM metallopeptidase domain 17 (ADAM17, ID 57027) was
downregulated by dex in the present study. It proteolytically
releases the pro-inflammatory TNF-a that triggers the secretion of
matrix metalloproteinases (MMPs) which in turn are involved in
blood brain barrier disruption [27]. Combined inhibition of
ADAM17 and MMPs in experimental models of BM resulted in
the attenuation of brain damage, preservation of learning
performance and reduced frequency of seizures [27,65].
Expressional data show a reduction of haematopoietic prostaglandin
D synthase (HPGDS, ID 58962) by dex. HPGDS is a key enzyme in
the production of prostaglandin D [66]. It is markedly induced
after focal cerebral ischemia followed by reperfusion and is mainly
produced by microglia. HPGDS protects against the detrimental
effects of cerebral infarction.
We observed a downregulation of serine or cysteine peptidase inhibitor
clade F member 1 (Serpinf1, ID 287526) by dex. The protein belongs
to the family of serine protease inhibitors. It exerts neurotrophic
effects on retinal and hippocampal cell neurons and acts as a pro-
inflammatory agent [67]. Serpinf1 changes microglial morphology
to a more deactivated state and induces production of CCL3 and
its receptors chemokine C-C motif receptor 3 (CCR3, ID: 117027) and
CCR5 (ID 117029), the latter one being downregulated by dex on
gene level. On protein level, we showed a decrease of two ligands
of CCR5 in tissue homogenates, namely CCL3 and CCL5. In vivo
it was shown that Serpinf1 is effective in protecting CNS neurons
from ischemic insult [68].
TSC22d3 was upregulated by dex in the hippocampus of
infected animals. The protein was shown to be expressed in
different cell types including neurons of the hippocampus
[69,70,71]. The expression was shown to be induced by GCs
and the protein mediates their anti-inflammatory effects [69,70].
For instance, in bone marrow mesenchymal stem cells it was
shown that TSC22d3 inhibits inflammatory-induced COX-2
expression by blocking NF-kappaB nucluear translocation [70].
Growth - Neurogenesis
The cellular and functional impairment of the hippocampus
following BM and its modulation by dex does not exclusively result
from regulation of genes associated with the category ‘‘apoptosis’’.
Genes belonging to ‘‘growth’’ may likewise determine the fate of
neuronal cells and decide on survival, neurogenesis or death.
We observed an upregulation of thrombopoietin (THPO, ID
81811) by dex in the hippocampus. In rat hippocampal neurons,
THPO induced cell death and the induction of pro-apoptotic
proteins most likely contributed to this effect [72]. Studies in PC12
cells indicated that THPO decreases neuronal survival by
suppressing NGF-induced ERK activity [73]. When primary
hippocampal neuronal cultures were challenged with hypoxia,
THPO decreased on mRNA and protein level [74]. Furthermore,
Axl receptor tyrosine kinase (Axl, ID 308444) was downregulated by
dex in the hippocampus. Axl was shown to be upregulated by
NGF in PC12 cells and in association with the NTRK1 it supports
neuronal differentiation and survival [75].
The neurotrophin NGF and the NTRK2 (ID 25054) and
NTRK3 (ID 29613) were found to be upregulated by dex in
qPCR assessment while NGFR was downregulated. The
differences were not detected in the microarray data which
might be due to the limited number of samples used and the
lower sensitivity of microarrays. Neurotrophin signalling
through NTRK receptors can regulate cell survival, prolifera-
tion, the fate of neural precursors, axon and dendrite growth
[76]. NGF determines neuronal survival by suppressing NGFR-
induced apoptotic signalling and by initiating survival through
the activation of NTRK1 [77]. As will be described in more
detail in the apoptosis section, PTPN6 can dephosphorylate
NTRK1 thus abolishing the pro-survival signal of increased
NGF expression. BDNF (ID 24225) and neurotrophin 5 (NTF5, ID
25730) are specific to NTRK2 while NT3 mainly activates
NTRK3 [78]. Each neurotrophin also binds to NGFR which
activates either synergistic or antagonistic processes to those
activated by NTRK binding [76,78]. In the present study, no
significant differences of neurotrophin mRNA or BDNF protein
level at three days after infection were detected when comparing
ID vs. IS. At five days after infection however, BDNF mRNA
and protein levels were increased by dex treatment [79]. The
observed upregulation of BDNF mRNA and protein already at
four days after infection suggests that dex is able to delay the
increase of BDNF [80]. Thus the previously observed beneficial
effects of BDNF on neuronal damage in BM may be delayed if
not even abolished by dex treatment [81].
We found expressional regulation of genes by dex in the
hippocampus which are involved in the pro-neurogenic TGF-b
signalling pathway. In the microarray data, an upregulation of
Tgfbr3 (ID 29610) and of TGF-b2 (ID 81809) by dex was
observed, while the Tgfbr1 (ID 29591) and Tgfbr2 (ID 81810)
were downregulated. qPCR analysis confirmed the downregula-
tion of Tgfbr2 by dex and showed furthermore a decrease of
TGF-b1. In adrenalectomized rats, as a correlate for GC
depletion, TGF-b1 expression was increased in the hippocampus
and correlated with the significant proliferation of newborn
neurons [82]. In addition, TGF-b1 exerts neuroprotection by the
induction of the transcriptional activity of NF-kappaB which in
turn promotes anti-apoptotic effects in cultured hippocampal
neurons [83]. Thus, we suggest that the downregulation of TGF-
b1 and the receptors 1 and 2 by dex results in a lack of pro-
neurogenic signalling via TGF-b pathway and a reduced
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induction of anti-apoptotic gene transcription both resulting in
increased apoptosis.
Ctnnb1 was observed to be upregulated in the hippocampus
by dex. The protein is involved in the canonical branch of the
pro-neurogenic Wnt signalling pathway [84,85]. When Ctnnb1
translocates to the nucleus, a complex is formed with
transcription factors of the T-cell factor/lymphoid enhancer
factor family to activate target genes [85]. In rat mammary
epithelial tumor cells, dex was able to upregulate Ctnnb1
transcript and protein expression and caused the protein to
localize predominantly at the cell membrane rather than the
nucleus [86]. Likewise, dex was shown to decrease the cytosolic
amount of Ctnnb1 and to inhibit the nuclear translocation of
Ctnnb1 both resulting in a suppression of the Wnt signal in
cultured human osteoblasts [85]. Studies in adult dentate gyrus
derived neural precursors showed opposite regulation of
proliferation by dex and lithium through contrariwise intranu-
clear translocation of Ctnnb1 [21]. The mood stabilizer lithium
was shown to induce adult hippocampal progenitors to become
neurons dependent on Wnt pathway components such as an
elevation of Ctnnb1 [84,85].
Apoptosis
During BM, apoptosis is observed in the hippocampal dentate
gyrus. The occurrence of cells showing characteristics of
apoptosis peaks at 36 h after infection and declines to control
levels until 72 h after infection [87]. In the present study which
focuses on regenerative processes subsequent to apoptosis, the
animals were sacrificed at 72 h after infection. Histopathological
evaluation showed the highest number of apoptotic cells in sham
infected control animals treated with dex. No significant
difference was observed when comparing ID vs. IS. We
hypothesize, that cells vulnerable to the pro-apoptotic effects of
dex undergo apoptosis and subsequent phagocytosis and clearing
before 72 h as a result of the infection while the apoptotic cascade
induced by dex treatment starts later in sham-infected control
animals to the result that apoptotic cells are still visible at 72 h.
This view is supported by the finding of upregulation of genes
that were associated to the category ‘‘apoptosis’’ when comparing
HCID vs. HCIS suggesting that dex prolongs processes of
apoptosis in infected animals.
Glutathione peroxidase 1 (Gpx1, ID 24404) was downregulated
by dex in the cortex and hippocampus and it was observed to be
upregulated during the acute phase of BM [2]. In Gpx1
knockout mice, increased neuronal cell death was demonstrated
following cerebral ischemia-reperfusion injury [88]. Studies in
primary neuronal cells lacking Gpx1 also showed increased
levels of cell death following the addition of exogenous hydrogen
peroxide. This correlated with a downregulation of the
activation of the phospho-inositide 3-kinase (PI3K) – Akt
survival pathway [88]. In contrast, inositol polyphosphate 59
phosphatase (INPP5D, ID 54259), which was downregulated by
dex in experimental PM, can negatively regulate the PI3K
signalling by hydrolization of the second messenger PI-3,4,5-
trisphosphate [89].
An upregulation of insulin-like growth factor binding protein 3
(IGFBP-3, ID 24484) was observed in the hippocampus by dex.
Studies on the protein level showed an induction in brain tissue
throughout early and late acute phase of PM in mice [55]. The
protein was shown to elicit anti-proliferative and pro-apoptotic
effects in an array of different cell systems [90].
Dex treatment increased mitochondrial apoptosis-inducing factor 3
(Aifm3, ID 303786) mRNA levels in the hippocampus and cortex.
Earlier studies revealed that the increase of apoptosis during PM is
not exclusively due to the activation of caspases. The bacteria itself
were able to damage mitochondria in microglia and neurons
which was followed by the release of Aifm3 [91]. Increased
expression by dex may reflect enhanced apoptosis.
PTPN6 was upregulated by the infection and downregulated by
dex in the hippocampus of infected animals. Western blot analysis
confirmed the results found on the microarrays. PTPN6 was found
to be expressed in astrocytes, microglia and neurons of the
hippocampus [77,92]. Cortical lesions led to an upregulation of
PTPN6 in activated microglia and astrocytes [92]. In PC12 cells
and neurons, PTPN6 dephosphorylated NTRK1 (ID 59109)
resulting in apoptosis [77].
Conclusion
By gene expression profiling, we documented the downregula-
tion of inflammatory processes by adjunctive dex treatment in
experimental PM. We detected diminished expression of genes
involved in the activation and migration of microglial cells
resulting in the observed reduction of chemokines on protein
level. Microglia are involved in the initial immune response against
PM by recognizing bacterial components via the toll-like receptors
2 and 4 subsequently releasing inflammatory mediators [45,93].
Furthermore, we observed a downregulation of ADAM17 which is
involved in TNF-a processing and blood brain barrier disruption
occurring in BM.
Dex treatment affected the expression of genes and pathways
regulating ‘‘apoptosis’’ or ‘‘growth’’ in experimental PM. The
expressional changes by dex lead to an enhancement of pro-
apoptotic processes or to a lack of pro-survival signals. These
findings may help to identify the mechanisms underlying the
observed increased apoptosis and learning difficulties by adjuvant
dex in experimental PM.
Supporting Information
Table S1 Microarray results of significantly different
genes when comparing samples of the hippocampus of
infected and dexamethasone-treated animalswith infect-
ed and saline-treated animals (ID vs. IS).
(DOC)
Table S2 Microarray results of significantly different
genes when comparing samples of the cortex of infected
and dexamethasone-treated animalswith infected and
saline-treated animals (ID vs. IS).
(DOC)




We thank Kevin Oberson, Franziska Simon and Angela Bu¨hlmann for
their technical assistance. Furthermore we want to thank Prof. Andreas
Papassotiropoulos for the possibility to use the Affymetrix core lab in the
Life Sciences Training Facility, Biozentrum, Basel to prepare and hybridise
the samples on GeneChipH Rat Exon 1.0 ST Arrays with the technical
assistance of Philippe Demougin.
Author Contributions
Conceived and designed the experiments: SLL MW DG. Performed the
experiments: CB. Analyzed the data: CB MW DG SLL. Wrote the paper:
CB MW DG SLL.
Dexamethasone in Pneumococcal Meningitis
PLoS ONE | www.plosone.org 12 March 2011 | Volume 6 | Issue 3 | e17840
References
1. Swartz MN (2004) Bacterial meningitis—a view of the past 90 years.
N Engl J Med 351: 1826–1828.
2. Coimbra RS, Voisin V, de Saizieu AB, Lindberg RL, Wittwer M, et al. (2006)
Gene expression in cortex and hippocampus during acute pneumococcal
meningitis. BMC Biol 4: 15.
3. Koedel U, Klein M, Pfister HW (2010) New understandings on the
pathophysiology of bacterial meningitis. Curr Opin Infect Dis 23: 217–223.
4. Andersen CO (2007) Streptococcus penumoniae meningitis. Clinical and
experimental studies. Dan Med Bull 54: 189–209.
5. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, et al. (1997)
Bacterial meningitis in the United States in 1995. Active Surveillance Team.
N Engl J Med 337: 970–976.
6. Thigpen MC, Rosenstein NE, Whitney CG, Lynfield R, Farley MM, et al.
Bacterial Meningitis in the United States – 1998–2003; 2005; San Francisco.
IDSA.
7. Koedel U, Scheld WM, Pfister HW (2002) Pathogenesis and pathophysiology of
pneumococcal meningitis. Lancet Infect Dis 2: 721–736.
8. Nau R, Soto A, Bruck W (1999) Apoptosis of neurons in the dentate gyrus in
humans suffering from bacterial meningitis. J Neuropathol Exp Neurol 58:
265–274.
9. Schunknecht HF, Montandon P (1970) Pathology of the ear in pneumococcal
meningitis. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 195: 207–225.
10. Sellner J, Ta¨uber MG, Leib SL (2010) Pathogenesis and pathophysiology of
bacterial CNS infections. In: Roos K. L TAR, ed. Bacterial Infections of the
Central Nervous System: Elsevier B. V. pp 1–16.
11. Brouwer MC, Heckenberg SG, de Gans J, Spanjaard L, Reitsma JB, et al.
Nationwide implementation of adjunctive dexamethasone therapy for pneumo-
coccal meningitis. Neurology 75: 1533–1539.
12. van de Beek D, Farrar JJ, de Gans J, Mai NT, Molyneux EM, et al. (2010)
Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual
patient data. Lancet Neurol 9: 254–263.
13. Leib SL, Heimgartner C, Bifrare YD, Loeffler JM, Taauber MG (2003)
Dexamethasone aggravates hippocampal apoptosis and learning deficiency in
pneumococcal meningitis in infant rats. Pediatr Res 54: 353–357.
14. Spreer A, Gerber J, Hanssen M, Schindler S, Hermann C, et al. (2006)
Dexamethasone increases hippocampal neuronal apoptosis in a rabbit model of
Escherichia coli meningitis. Pediatr Res 60: 210–215.
15. Zysk G, Bruck W, Gerber J, Bruck Y, Prange HW, et al. (1996) Anti-
inflammatory treatment influences neuronal apoptotic cell death in the dentate
gyrus in experimental pneumococcal meningitis. J Neuropathol Exp Neurol 55:
722–728.
16. Addison J, Kim HH, Richter CP (2006) Cochlear preservation after meningitis:
an animal model confirmation of adjunctive steroid therapy. Laryngoscope 116:
279–282.
17. Kim HH, Addison J, Suh E, Trune DR, Richter CP (2007) Otoprotective effects
of dexamethasone in the management of pneumococcal meningitis: an animal
study. Laryngoscope 117: 1209–1215.
18. Rappaport JM, Bhatt SM, Burkard RF, Merchant SN, Nadol JB, Jr. (1999)
Prevention of hearing loss in experimental pneumococcal meningitis by
administration of dexamethasone and ketorolac. J Infect Dis 179: 264–268.
19. Irazuzta J, Pretzlaff RK, DeCourten-Myers G, Zemlan F, Zingarelli B (2005)
Dexamethasone decreases neurological sequelae and caspase activity. Intensive
Care Med 31: 146–150.
20. Wittwer M, Grandgirard D, Rohrbach J, Leib SL (2010) Tracking the
transcriptional host response from the acute to the regenerative phase of
experimental pneumococcal meningitis. BMC Infect Dis 10: 176.
21. Boku S, Nakagawa S, Masuda T, Nishikawa H, Kato A, et al. (2009)
Glucocorticoids and lithium reciprocally regulate the proliferation of adult
dentate gyrus-derived neural precursor cells through GSK-3beta and beta-
catenin/TCF pathway. Neuropsychopharmacology 34: 805–815.
22. Mundy WR, Radio NM, Freudenrich TM (2010) Neuronal models for
evaluation of proliferation in vitro using high content screening. Toxicology
270: 121–130.
23. Yu S, Patchev AV, Wu Y, Lu J, Holsboer F, et al. (2010) Depletion of the neural
precursor cell pool by glucocorticoids. Ann Neurol 67: 21–30.
24. Kim JB, Ju JY, Kim JH, Kim TY, Yang BH, et al. (2004) Dexamethasone
inhibits proliferation of adult hippocampal neurogenesis in vivo and in vitro.
Brain Res 1027: 1–10.
25. Grandgirard D, Oberson K, Buhlmann A, Gaumann R, Leib SL (2010)
Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic
antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal
meningitis. Antimicrob Agents Chemother 54: 1323–1326.
26. Coimbra RS, Loquet G, Leib SL (2007) Limited efficacy of adjuvant therapy
with dexamethasone in preventing hearing loss due to experimental pneumo-
coccal meningitis in the infant rat. Pediatr Res 62: 291–294.
27. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, et al. (2001)
Inhibition of matrix metalloproteinases and tumour necrosis factor alpha
converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 124:
1734–1742.
28. Sanges R, Cordero F, Calogero RA (2007) oneChannelGUI: a graphical
interface to Bioconductor tools, designed for life scientists who are not familiar
with R language. Bioinformatics 23: 3406–3408.
29. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004)
Bioconductor: open software development for computational biology and
bioinformatics. Genome Biol 5: R80.
30. R Development Core Team (2010) R: A language and environment for
statistical computing. R Project Manual. Vienna: R foundation for statistical
computing.
31. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003)
Exploration, normalization, and summaries of high density oligonucleotide array
probe level data. Biostatistics 4: 249–264.
32. Smyth GK (2005) Limma: Linear models for microarray data. In:
Gentleman RC, Carey VJ, Huber W, Irizarry RA, Dudoit S, eds. Bioinformatics
and Computational Biology Solutions using R and Bioconductor. New York:
Springer. pp 397–420.
33. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A
Practical and Powerful Approach to Multiple Testing. Journal of the Royal
Statistical Society Series B (Methodological) 57: 289–300.
34. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID:
Database for Annotation, Visualization, and Integrated Discovery. Genome Biol
4: P3.
35. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:
44–57.
36. Gillett A, Maratou K, Fewings C, Harris RA, Jagodic M, et al. (2009)
Alternative splicing and transcriptome profiling of experimental autoimmune
encephalomyelitis using genome-wide exon arrays. PLoS One 4: e7773.
37. Applied Biosystems (2006) Amplification Efficiency of TaqMan Gene Expression
assays. USA: Applied Biosystems Application Note.
38. de Jonge HJ, Fehrmann RS, de Bont ES, Hofstra RM, Gerbens F, et al. (2007)
Evidence based selection of housekeeping genes. PLoS One 2: e898.
39. Bookout AL, Mangelsdorf DJ (2003) Quantitative real-time PCR protocol for
analysis of nuclear receptor signaling pathways. Nucl Recept Signal 1: e012.
40. Gehre F, Leib SL, Grandgirard D, Kummer J, Buhlmann A, et al. (2008)
Essential role of choline for pneumococcal virulence in an experimental model of
meningitis. J Intern Med 264: 143–154.
41. French PJ, Peeters J, Horsman S, Duijm E, Siccama I, et al. (2007) Identification
of differentially regulated splice variants and novel exons in glial brain tumors
using exon expression arrays. Cancer Res 67: 5635–5642.
42. Schutte M, Elstrodt F, Bralten LB, Nagel JH, Duijm E, et al. (2008) Exon
expression arrays as a tool to identify new cancer genes. PLoS One 3: e3007.
43. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. (2006) The
RIN: an RNA integrity number for assigning integrity values to RNA
measurements. BMC Mol Biol 7: 3.
44. Soverchia L, Ubaldi M, Leonardi-Essmann F, Ciccocioppo R, Hardiman G
(2005) Microarrays--the challenge of preparing brain tissue samples. Addict Biol
10: 5–13.
45. Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, et al. (2004) Role of
microglia in central nervous system infections. Clin Microbiol Rev 17: 942–964,
table of contents.
46. Grandgirard D, Bifrare YD, Pleasure SJ, Kummer J, Leib SL, et al. (2007)
Pneumococcal meningitis induces apoptosis in recently postmitotic immature
neurons in the dentate gyrus of neonatal rats. Dev Neurosci 29: 134–142.
47. Hofer S, Grandgirard D, Trachsel T, Leib SL Apoptosis of neurogenic cells in
an in vitro model of bacterial meningitis; 2010; Vienna (Austria).
48. Barnes PJ (2010) Mechanisms and resistance in glucocorticoid control of
inflammation. J Steroid Biochem Mol Biol 120: 76–85.
49. Zhang Z, Artelt M, Burnet M, Schluesener HJ (2007) Dexamethasone attenuates
early expression of three molecules associated with microglia/macrophages
activation following rat traumatic brain injury. Acta Neuropathol 113: 675–682.
50. Liang J, Takeuchi H, Doi Y, Kawanokuchi J, Sonobe Y, et al. (2008) Excitatory
amino acid transporter expression by astrocytes is neuroprotective against
microglial excitotoxicity. Brain Res 1210: 11–19.
51. Spranger M, Krempien S, Schwab S, Maiwald M, Bruno K, et al. (1996) Excess
glutamate in the cerebrospinal fluid in bacterial meningitis. J Neurol Sci 143:
126–131.
52. Klein M, Koedel U, Kastenbauer S, Pfister HW (2008) Nitrogen and oxygen
molecules in meningitis-associated labyrinthitis and hearing impairment.
Infection 36: 2–14.
53. Hanisch UK, Prinz M, Angstwurm K, Hausler KG, Kann O, et al. (2001) The
protein tyrosine kinase inhibitor AG126 prevents the massive microglial cytokine
induction by pneumococcal cell walls. Eur J Immunol 31: 2104–2115.
54. Diab A, Abdalla H, Li HL, Shi FD, Zhu J, et al. (1999) Neutralization of
macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates
neutrophil recruitment in the central nervous system during experimental
bacterial meningitis. Infect Immun 67: 2590–2601.
55. Klein M, Paul R, Angele B, Popp B, Pfister HW, et al. (2006) Protein expression
pattern in experimental pneumococcal meningitis. Microbes Infect 8: 974–983.
56. Zhou Y, Ling EA, Dheen ST (2007) Dexamethasone suppresses monocyte
chemoattractant protein-1 production via mitogen activated protein kinase
phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-
activated protein kinase in activated rat microglia. J Neurochem 102: 667–678.
Dexamethasone in Pneumococcal Meningitis
PLoS ONE | www.plosone.org 13 March 2011 | Volume 6 | Issue 3 | e17840
57. Newton R, King EM, Gong W, Rider CF, Staples KJ, et al. (2010)
Glucocorticoids inhibit IL-1beta-induced GM-CSF expression at multiple levels:
roles for the ERK pathway and repression by MKP-1. Biochem J 427: 113–124.
58. Tarozzo G, Campanella M, Ghiani M, Bulfone A, Beltramo M (2002)
Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-
reperfusion brain injury in the rat. Eur J Neurosci 15: 1663–1668.
59. Inoue K (2007) UDP facilitates microglial phagocytosis through P2Y6 receptors.
Cell Adh Migr 1: 131–132.
60. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, et al. (2006) The
P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat
Neurosci 9: 1512–1519.
61. Kettenmann H (2007) Neuroscience: the brain’s garbage men. Nature 446:
987–989.
62. Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K,
et al. (2007) UDP acting at P2Y6 receptors is a mediator of microglial
phagocytosis. Nature 446: 1091–1095.
63. Takagi Y, Harada J, Chiarugi A, Moskowitz MA (2002) STAT1 is activated in
neurons after ischemia and contributes to ischemic brain injury. J Cereb Blood
Flow Metab 22: 1311–1318.
64. Hu X, Li WP, Meng C, Ivashkiv LB (2003) Inhibition of IFN-gamma signaling
by glucocorticoids. J Immunol 170: 4833–4839.
65. Meli DN, Loeffler JM, Baumann P, Neumann U, Buhl T, et al. (2004) In
pneumococcal meningitis a novel water-soluble inhibitor of matrix metallopro-
teinases and TNF-alpha converting enzyme attenuates seizures and injury of the
cerebral cortex. J Neuroimmunol 151: 6–11.
66. Liu M, Eguchi N, Yamasaki Y, Urade Y, Hattori N, et al. (2009) Protective role
of hematopoietic prostaglandin D synthase in transient focal cerebral ischemia in
mice. Neuroscience 163: 296–307.
67. Takanohashi A, Yabe T, Schwartz JP (2005) Pigment epithelium-derived factor
induces the production of chemokines by rat microglia. Glia 51: 266–278.
68. Sanagi T, Yabe T, Yamada H (2008) Gene transfer of PEDF attenuates ischemic
brain damage in the rat middle cerebral artery occlusion model. J Neurochem
106: 1841–1854.
69. Eddleston J, Herschbach J, Wagelie-Steffen AL, Christiansen SC, Zuraw BL
(2007) The anti-inflammatory effect of glucocorticoids is mediated by
glucocorticoid-induced leucine zipper in epithelial cells. J Allergy Clin Immunol
119: 115–122.
70. Yang N, Zhang W, Shi XM (2008) Glucocorticoid-induced leucine zipper
(GILZ) mediates glucocorticoid action and inhibits inflammatory cytokine-
induced COX-2 expression. J Cell Biochem 103: 1760–1771.
71. Yachi K, Inoue K, Tanaka H, Yoshikawa H, Tohyama M (2007) Localization of
glucocorticoid-induced leucine zipper (GILZ) expressing neurons in the central
nervous system and its relationship to the stress response. Brain Res 1159:
141–147.
72. Byts N, Samoylenko A, Woldt H, Ehrenreich H, Siren AL (2006) Cell type
specific signalling by hematopoietic growth factors in neural cells. Neurochem
Res 31: 1219–1230.
73. Samoylenko A, Byts N, Rajalingam K, von Ahsen N, Rapp UR, et al. (2008)
Thrombopoietin inhibits nerve growth factor-induced neuronal differentiation
and ERK signalling. Cell Signal 20: 154–162.
74. Ehrenreich H, Hasselblatt M, Knerlich F, von Ahsen N, Jacob S, et al. (2005) A
hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the
brain. Proc Natl Acad Sci U S A 102: 862–867.
75. Zheng Y, Zhang L, Lu Q, Wang X, Yu F (2009) NGF-induced Tyro3 and Axl
function as survival factors for differentiating PC12 cells. Biochem Biophys Res
Commun 378: 371–375.
76. Huang EJ, Reichardt LF (2003) Trk receptors: roles in neuronal signal
transduction. Annu Rev Biochem 72: 609–642.
77. Marsh HN, Dubreuil CI, Quevedo C, Lee A, Majdan M, et al. (2003) SHP-1
negatively regulates neuronal survival by functioning as a TrkA phosphatase.
J Cell Biol 163: 999–1010.
78. Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development
and function. Annu Rev Neurosci 24: 677–736.
79. Li L, Shui QX, Zhao ZY (2003) Regulation of brain-derived neurotrophic factor
(BDNF) expression following antibiotic treatment of experimental bacterial
meningitis. J Child Neurol 18: 828–834.
80. Tauber SC, Stadelmann C, Spreer A, Bruck W, Nau R, et al. (2005) Increased
expression of BDNF and proliferation of dentate granule cells after bacterial
meningitis. J Neuropathol Exp Neurol 64: 806–815.
81. Bifrare YD, Kummer J, Joss P, Tauber MG, Leib SL (2005) Brain-derived
neurotrophic factor protects against multiple forms of brain injury in bacterial
meningitis. J Infect Dis 191: 40–45.
82. Battista D, Ferrari CC, Gage FH, Pitossi FJ (2006) Neurogenic niche modulation
by activated microglia: transforming growth factor beta increases neurogenesis
in the adult dentate gyrus. Eur J Neurosci 23: 83–93.
83. Zhu Y, Culmsee C, Klumpp S, Krieglstein J (2004) Neuroprotection by
transforming growth factor-beta1 involves activation of nuclear factor-kappaB
through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein
kinase-extracellular-signal regulated kinase1,2 signaling pathways. Neuroscience
123: 897–906.
84. Wexler EM, Geschwind DH, Palmer TD (2008) Lithium regulates adult
hippocampal progenitor development through canonical Wnt pathway activa-
tion. Mol Psychiatry 13: 285–292.
85. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R (2005)
Glucocorticoid suppresses the canonical Wnt signal in cultured human
osteoblasts. Biochem Biophys Res Commun 329: 177–181.
86. Guan Y, Rubenstein NM, Failor KL, Woo PL, Firestone GL (2004)
Glucocorticoids control beta-catenin protein expression and localization through
distinct pathways that can be uncoupled by disruption of signaling events
required for tight junction formation in rat mammary epithelial tumor cells. Mol
Endocrinol 18: 214–227.
87. Gianinazzi C, Grandgirard D, Imboden H, Egger L, Meli DN, et al. (2003)
Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis. Acta
Neuropathol 105: 499–507.
88. Taylor JM, Ali U, Iannello RC, Hertzog P, Crack PJ (2005) Diminished Akt
phosphorylation in neurons lacking glutathione peroxidase-1 (Gpx1) leads to
increased susceptibility to oxidative stress-induced cell death. J Neurochem 92:
283–293.
89. Kalesnikoff J, Sly LM, Hughes MR, Buchse T, Rauh MJ, et al. (2003) The role
of SHIP in cytokine-induced signaling. Rev Physiol Biochem Pharmacol 149:
87–103.
90. Jogie-Brahim S, Feldman D, Oh Y (2009) Unraveling insulin-like growth factor
binding protein-3 actions in human disease. Endocr Rev 30: 417–437.
91. Braun JS, Novak R, Murray PJ, Eischen CM, Susin SA, et al. (2001) Apoptosis-
inducing factor mediates microglial and neuronal apoptosis caused by
pneumococcus. J Infect Dis 184: 1300–1309.
92. Horvat A, Schwaiger F, Hager G, Brocker F, Streif R, et al. (2001) A novel role
for protein tyrosine phosphatase shp1 in controlling glial activation in the normal
and injured nervous system. J Neurosci 21: 865–874.
93. Klein M, Obermaier B, Angele B, Pfister HW, Wagner H, et al. (2008) Innate
immunity to pneumococcal infection of the central nervous system depends on
toll-like receptor (TLR) 2 and TLR4. J Infect Dis 198: 1028–1036.
Dexamethasone in Pneumococcal Meningitis
PLoS ONE | www.plosone.org 14 March 2011 | Volume 6 | Issue 3 | e17840
